In April 2003, rumours spread that smoking protected patients from developing SARS (Severe Acute Respiratory Syndrome). In a case-control study of 447 patients who attended a SARS screening clinic, 63 patients were admitted with SARS. Although a higher proportion of SARS cases were non-smokers than smokers, the adjusted odds of non-smokers with SARS was 1.7 (p=0.54). There is no evidence that smoking protects patients from developing SARS.
Introduction
Severe acute respiratory syndrome (SARS) is a lifethreatening, emerging infectious disease 1 caused by a novel coronavirus. 2 Cigarette smoking is an important environmental risk factor 3 and in April 2003, rumours spread that there were fewer smokers amongst the cases reported in Guangdong, a province in southern China, and that smoking might cure SARS. 4 Hong Kong's Department of Health moved quickly to squash these rumours stating that they were 'totally unfounded'. 4 However, presently there is no evidence in the literature either to confirm or refute these suggestions. The World Health Organisation have set up an international, multicentre, collaborative group to research on SARS 5 and it is important that potential prophylactic or therapeutic agents be identified for further evaluation. In a case-control study, we therefore investigated smoking as a risk factor for SARS using data collected prospectively during the SARS outbreak at the Prince of Wales Hospital in Hong Kong.
Patients and methods
In this case-control study, 447 patients attended the SARS clinic based at the Prince of Wales Hospital, Hong Kong, between 12th March and 14th May 2003, and had complete SARS-coronavirus (SARS-CoV) serology. SARS was defined clinically as fever >38°C, radiological infiltrates compatible with pneumonia, a typical clinical course, and positive SARS-CoV infection serology. 6 The reference standard was positive SARS-CoV serology 7 and SARS was confirmed if any one of three criteria was met: (a) a four-fold rise in SARS-CoV antibody titre between acute (taken within 7 days after the onset of fever) and convalescent (taken >21 days after the onset of fever) phase serum; (b) detection of antibody to SARSCoV in specimens during acute illness; or (c) detection of antibody to SARS-CoV in specimens obtained from convalescent serum. Serologically negative cases were defined as the absence of antibody to SARS coronavirus in convalescent serum taken >21 days after symptom onset. 7 Blood was taken for SARS-CoV serology at first presentation and at >21 days after the onset of symptoms wherever possible. Cigarette smokers were defined as people who had smoked cigarettes at all in the previous month.
Results
Sixty-three patients were admitted to hospital with probable SARS, and 48 had confirmed SARS. The mean (SD) time from symptom onset to attending the clinic was 3.3 (2.6) days. In patients admitted to hospital the mean (SD) time from symptom onset to admission was 4.7 (3.5) days. Mean duration of follow up in patients who were not admitted was 10 (11) days. Table 1 shows the patient demographics and SARSCoV serology. Significant confounders include gender, hospital occupation and contact history. There were significant differences in the proportion of presenting systemic, respiratory or abdominal symptoms or of preadmission temperature between the smokers and non-smokers who attended the SARS clinic. Hazard ratios for SARS were calculated before and after age and sex adjustments with case-control comparisons and are presented in Table 2 . Further adjustments were also made for the three major confounders.
Discussion
The results in this study show that smoking does not protect patients from contracting SARS. In this cohort a greater proportion of non-smokers contracted SARS 
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